Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis.

A retrospective cost-effectiveness analysis, from the institutional perspective, was performed on the 1637 clinically evaluable patients who participated in randomised studies of cefepime versus ceftazidime. The clinical success rate was 88% for patients in both the cefepime and ceftazidime groups. Adverse events occurred in 16.5% of cefepime and 19.0% of ceftazidime patients (p greater than 0.05). In most cases cefepime was administered every 12 hours while ceftazidime was administered every 8 hours. The amount of drug administered per patient (mean+/-SEM) was 17.6+/-0.4g of cefepime and 29.1+/-0.8g of ceftazidime (p less than 0.01). The median number of days of antibiotic treatment was 8 for each group. Decision and sensitivity analyses of drug price and hospital bed cost demonstrated that cefepime was consistently more cost effective than ceftazidime. The probability of clinical success varied between 60 and 97% and revealed that ceftazidime would have to be 31% more effective than cefepime to change the economic decision. If the acquisition prices per gram of drug are similar, cefepime will be cost effective compared with ceftazidime.